FDA Class II Recall: Lannett's Dextroamphetamine Tablets Impact Supply Chain and Regulatory Compliance
Lannett Company Inc. has initiated a Class II recall for 4,848 bottles of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets due to foreign tablet contamination. This voluntary recall, stemming from a 5mg tablet found in 10mg bottles, signals critical quality control deficiencies. Procurement and regulatory teams must assess supply chain resilience and potential market disruptions for this controlled substance.
FDA Class II Recall: Lannett's Dextroamphetamine Product Contamination Event
Lannett Company Inc. has initiated a Class II voluntary recall, D-0642-2025, for a significant quantity of its Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets. This event, reported on 2025-09-17, specifically impacts Lot#: 25283185A, with an expiry date of 02/28/2027. The recall was triggered by the presence of a foreign tablet: two bottles, explicitly labeled as 10mg strength (NDC 0527-0762-37), were found to contain one 5mg tablet of the same drug combination. A total of 4,848 bottles of the 10mg product are affected. This classification signifies that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. For procurement directors, this means an immediate assessment of inventory and alternative sourcing is critical to mitigate potential disruptions. Regulatory affairs heads must understand that while voluntary, this firm-initiated action highlights a breach in Good Manufacturing Practices (GMP) that the FDA will scrutinize. The product, identified by application number ANDA215565, is a human prescription drug administered orally, distributed by Lannett Company, Inc. from Philadelphia, PA 19136, with the recalling firm's address located in Seymour, IN 47274-3342. This incident underscores the imperative for robust quality assurance protocols throughout the entire manufacturing and packaging process.
Manufacturing Quality Breach: Implications for Supply Chain Integrity of Controlled Substances
The presence of a 5mg tablet within a bottle labeled for 10mg Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets represents a critical failure in Lannett Company Inc.'s quality control systems. For supply chain VPs, this is not merely a product mix-up; it signals potential systemic vulnerabilities in segregation, line clearance, or automated inspection processes. Such an error, particularly with a controlled substance like amphetamine combinations, carries heightened risks. Patients receiving a lower dose than prescribed could experience inadequate therapeutic effect, while those inadvertently receiving a higher dose could face adverse reactions. This directly impacts patient safety and trust in generic pharmaceuticals. The distribution pattern, limited to Ohio, suggests a contained initial impact, but the underlying manufacturing issue could affect other lots or products. Business development executives must consider the reputational damage and the potential for increased regulatory oversight, which could delay future product approvals or market expansions. The FDA's Class II classification, completed on 2025-09-11, mandates careful monitoring by all stakeholders, as it indicates a reasonable probability of adverse health consequences. This incident necessitates a thorough review of supplier qualification criteria, emphasizing audit trails for packaging and labeling accuracy, especially for high-potency or controlled substances where dosage precision is paramount.
Commercial Impact and Market Repercussions for Dextroamphetamine Supply
The recall of 4,848 bottles of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets by Lannett Company Inc. carries tangible commercial repercussions. For procurement directors, this quantity, while not a national shortage, represents a localized disruption in Ohio, requiring immediate contingency planning. The generic market for amphetamine combination products is competitive, and any supply interruption can prompt customers to seek alternative suppliers, potentially eroding Lannett's market share. Business development executives must anticipate questions from existing and prospective clients regarding quality assurance and supply reliability. The cost associated with managing a recall—including product retrieval, destruction, customer communication, and internal investigations—will directly impact Lannett's profitability. Furthermore, the incident could trigger increased scrutiny from wholesalers and pharmacies, leading to more rigorous quality checks or even temporary de-listing of Lannett's products until confidence is restored. While the recall is firm-initiated and completed, the underlying cause of foreign tablet presence suggests a manufacturing process vulnerability that could affect future production runs. This event serves as a stark reminder that even seemingly minor quality deviations can have significant financial and reputational consequences, necessitating proactive risk management strategies for all participants in the pharmaceutical supply chain.
Regulatory Scrutiny and Future Compliance Outlook for Lannett Company Inc.
This Class II recall by Lannett Company Inc. places the firm under increased regulatory scrutiny from the FDA. While the recall was voluntary and firm-initiated, the agency's classification and monitoring of such events are rigorous. Regulatory affairs heads should anticipate potential follow-up actions from the FDA, which could include requests for detailed root cause analyses, corrective and preventive action (CAPA) plans, and possibly an inspection of the Seymour, IN facility or other relevant sites involved in the manufacturing and packaging of ANDA215565. The presence of a foreign tablet indicates a failure to adhere to current Good Manufacturing Practices (cGMP), specifically concerning product identity, strength, quality, and purity. Such deficiencies can lead to more severe enforcement actions if not adequately addressed. In the broader regulatory landscape, similar quality issues have led to significant consequences for other firms; for instance, Essential Wellness Pharma faced a Class II recall for sterility failures in 2026, underscoring the FDA's consistent focus on manufacturing quality. Although not directly related to Lannett, these parallel events highlight the agency's vigilance. Lannett's ability to demonstrate effective remediation will be critical in mitigating future regulatory risks, including potential Warning Letters or even import alerts if the issue were to recur or be deemed more widespread. This event necessitates a proactive and transparent engagement with the FDA to restore confidence in their quality systems.
Strategic Considerations for Procurement and Supply Chain Resilience
For procurement directors and supply chain VPs, the Lannett Company Inc. recall of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets serves as a critical case study in supplier risk management. The incident underscores the necessity of diversifying sourcing strategies, particularly for essential medicines and controlled substances where supply disruptions can have significant patient impact. Relying on a single supplier for key active pharmaceutical ingredients (APIs) or finished dosage forms, even for generic products like those under ANDA215565, exposes organizations to unacceptable risk. Proactive measures include conducting regular, comprehensive audits of all suppliers, focusing not just on financial stability but also on the robustness of their quality management systems, specifically packaging and labeling controls. Establishing secondary and tertiary qualified suppliers, even if not immediately utilized, is a strategic imperative. Furthermore, implementing advanced analytics to monitor FDA recall data and other regulatory intelligence signals can provide early warnings of potential supply chain vulnerabilities. Business development executives should leverage these insights to build more resilient supply networks, ensuring continuity of supply and protecting brand reputation. This event reinforces that a robust risk mitigation framework, encompassing both pre-qualification and ongoing performance monitoring, is indispensable in today's complex global chemical and life sciences industry.